CD4 and neoplasm: Surprisingly, when it comes to personalized neoantigen vaccines, it has been suggested that the majority of the immunogenic mutanome is recognized by CD4+ T cells in tumor-bearing C57BL/6 mice 62, further emphasizing the necessity of involving CD4+ T cell responses in anti-tumor immunity.